ABSTRACT
with self-administration. Four patients with
INTRODUCTION
Intravenous immunoglobulin (IVIG) has been the preferred route of therapy for primary immune deficiencies since the early 1980s. Subcutaneous immunoglobulin (SCIG) administration was first described by Bruton in 1952 . 1 Later, SCIG administration with small pumps was introduced in the United States (US) and became widely used in Sweden and Norway. [2] [3] [4] Positive treatment experience increased the popularity of the subcutaneous route among physicians and patients elsewhere. 5, 6 SCIG therapy obviates the need for venous access, maintains stable serum IgG levels, offers fewer systemic adverse events (AEs) when compared to IVIG, and is amenable to self-infusion. [7] [8] [9] Self-infusion and home administration allow flexibility in adapting to the patient's own schedule and are associated with improved quality of life compared to hospital or office-based intravenous treatment. [10] [11] [12] Recent IVIG products are still given mostly at a clinic, doctor's office, or infusion center.
Recently developed SCIG preparations offer more rapid infusion in addition to good efficacy and tolerability. These technological advancements prompt reconsideration of the use of SCIG in different indications currently reserved for IVIG.
In current practice, SCIG has mainly been used for maintenance replacement therapy in primary immunodeficiency (PI), while IVIG is used for initiation and maintenance of replacement therapy and for the high doses required in immunomodulatory therapy.
However, SCIG has the potential to play a more important role in indications besides PI, such as neuropathies and myopathies. Here, the authors review emerging developments in the use of SCIG. 
METHODS

SCIG IN INITIATION OF REPLACEMENT THERAPY
Traditionally, maintenance replacement SCIG therapy is preceded by a switch from existing IVIG therapy. Different regimens for initiating SCIG have been tested, but usually the first subcutaneous infusion is given 1 week after the last intravenous infusion in order to maintain high serum IgG levels. [13] [14] [15] Thereafter, the average daily IgG level achieved with IVIG can be maintained with regular subcutaneous infusions ( Figure 1 ). Alternatively, however, the IgG loading can be achieved directly with SCIG.
Study of SCIG in Previously Untreated
Patients with PI
A recently completed open-label, single-arm, Figure 2B ) 16 and remained stable for the entire 6-month maintenance phase of the study.
The study design allowed dose adjustments in week 3; however, no patient required dose adjustment. The doses chosen at study start were maintained throughout the study and were effective in all patients. The use of SCIG instead of IVIG in maintenance therapy in MMN, polymyositis, and dermatomyositis has been reported recently.
30-34
Crossover study of SCIG and IVIG in MMN
In a randomized, single-blinded, crossover study, nine MMN patients who showed a good response to previous IVIG therapy were enrolled.
Responsiveness to IgG therapy was defined as a B.
decrease of ≥10% in combined dynamometric strength of one or more muscle groups in a prestudy, treatment-free period of a maximum 10 weeks. 32 Prior to entering the main study, in each group). 31 In case of worsening of disease symptoms, the low dose could be doubled.
The primary endpoint was muscle strength in 10 predefined bilateral muscle groups, evaluated using the Medical Research Council Scale.
In the low-dose group, one patient discontinued the study due to injection site reactions (local swelling and pain) and the remaining four similar to those at study start and had stable or Clinical scores as function of IgG trough levels in one patient who discontinued due to treatment failure. Worsening in muscle strength, disability score and motor function score, in the MMN patient who discontinued due to treatment failure is shown together with serum IgG concentrations (IgG and motor function data available only for baseline and week 8 due to discontinuation after week 12). Muscle strength score was determined as described for Figure 3B . Disability was assessed using a modified Guy's Neurological Disability scale. The scale ranges from 0-10 points, with 10 meaning inability to use arms and legs. Motor function score was based on 4 individually defined tasks. 
SCIG Therapy in Other Neuropathies
Two case reports of the use of SCIG in the maintenance of CIDP demonstrated stabilization of patients with monthly doses equivalent to previous IVIG treatment. 33 The weekly dose was administered either once per week or on three consecutive days per week. Tolerability was good, with only local reactions observed.
Initiation of immunomodulation therapy
with SCIG in patients with polymyositis or dermatomyositis was reported recently. 30 Although six of the seven patients had been treated with IVIG at some point, four were not receiving IVIG at the start of the study. In these patients, SCIG therapy was initiated by once weekly administration of 0.2 g/kg/week, resulting in improved serum creatine kinase levels and muscle strength. 30 Apart from mild local reactions in two patients, no major AEs were observed.
DISCUSSION
The Importance of Stable Trough IgG Levels
Despite the small patient populations in the studies described above, it appears that both intravenous and subcutaneous regimens can be used in the initiation of replacement therapy in PI and maintenance of patients with MMN.
It has been suggested that a minimal IgG concentration (5 g/L) is required for protection from infections in immunodeficiencies [35] [36] [37] and that higher serum IgG levels result in better protection. [38] [39] [40] The correlation between IgG levels and clinical outcomes in MMN is illustrated with data for one patient from the smooth transition protocol study, whose IgG levels failed to increase, probably due to the low body fat, with associated worsening of disease symptoms (see Figure 3C ). 34 
New Products Allow Faster Subcutaneous Infusions
Preparations for intramuscular immunoglobulin (IMIG) administration were the first products to be infused subcutaneously. 8, 9, 52 Infusions were initially very slow (10-20 mL over several hours), but as the improved tolerability of SCIG was recognized, infusion rates were increased. 3, 11, 53 Currently available 16%
products are infused at 10-20 mL (1.6-3.2 g) per hour (Table 2) . 14, 15 The recent introduction of a 20% product (Hizentra), specifically formulated for subcutaneous use, allowed even higher 
